2020 Q3 Form 10-Q Financial Statement

#000156459020048950 Filed on October 29, 2020

View on sec.gov

Income Statement

Concept 2020 Q3 2019 Q3 2019 Q2
Revenue $29.19M $22.85M $22.48M
YoY Change 27.75% 18.21% 45.78%
Cost Of Revenue $10.95M $7.580M $8.111M
YoY Change 44.46% -6.88% 5.06%
Gross Profit $18.24M $15.26M $14.36M
YoY Change 19.53% 36.37% 86.49%
Gross Profit Margin 62.49% 66.78% 63.88%
Selling, General & Admin $16.30M $16.14M $16.74M
YoY Change 0.99% 15.62% 15.95%
% of Gross Profit 89.36% 105.77% 116.57%
Research & Development $15.92M $16.08M $14.42M
YoY Change -1.0% 48.48% 45.94%
% of Gross Profit 87.28% 105.37% 100.42%
Depreciation & Amortization $810.0K -$130.0K $1.180M
YoY Change -723.08% -140.62% 210.53%
% of Gross Profit 4.44% -0.85% 8.22%
Operating Expenses $32.22M $32.22M $16.74M
YoY Change 0.0% 29.97% -31.16%
Operating Profit -$13.98M -$16.96M -$2.380M
YoY Change -17.57% 24.71% -81.07%
Interest Expense -$440.0K -$1.290M -$1.050M
YoY Change -65.89% 22.86% -209.6%
% of Operating Profit
Other Income/Expense, Net $350.0K $340.0K -$708.0K
YoY Change 2.94% -33.33% 8.59%
Pretax Income -$14.07M -$17.91M -$17.50M
YoY Change -21.44% 26.66% 32.35%
Income Tax $70.00K $60.00K $60.00K
% Of Pretax Income
Net Earnings -$14.14M -$17.97M -$17.56M
YoY Change -21.31% 26.6% 32.22%
Net Earnings / Revenue -48.44% -78.63% -78.12%
Basic Earnings Per Share -$0.13 -$0.13
Diluted Earnings Per Share -$84.89K -$0.13 -$0.13
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q3 2019 Q3 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $135.1M $85.10M $96.20M
YoY Change 58.75% -28.48% -14.03%
Cash & Equivalents $31.47M $27.10M $23.54M
Short-Term Investments $106.2M $60.70M $72.66M
Other Short-Term Assets $6.500M $5.800M $8.800M
YoY Change 12.07% -21.62% 77.06%
Inventory $19.46M $20.91M $17.45M
Prepaid Expenses
Receivables $16.20M $14.50M $13.43M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $177.3M $126.3M $135.8M
YoY Change 40.38% -15.91% -3.8%
LONG-TERM ASSETS
Property, Plant & Equipment $27.70M $29.30M $15.35M
YoY Change -5.46% 845.16% 611.4%
Goodwill $1.316M
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $7.000M $7.300M $4.802M
YoY Change -4.11% 8.96% 19.72%
Total Long-Term Assets $36.10M $38.10M $38.79M
YoY Change -5.25% 231.3% 264.29%
TOTAL ASSETS
Total Short-Term Assets $177.3M $126.3M $135.8M
Total Long-Term Assets $36.10M $38.10M $38.79M
Total Assets $213.4M $164.4M $174.6M
YoY Change 29.81% 1.67% 15.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $19.20M $20.00M $21.06M
YoY Change -4.0% 53.85% 86.24%
Accrued Expenses $19.55M $18.45M $16.65M
YoY Change 5.94% 1.93% 33.15%
Deferred Revenue $665.0K
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $5.000M $5.000M $4.500M
YoY Change 0.0% -12.28% 25.0%
Total Short-Term Liabilities $46.20M $45.60M $50.78M
YoY Change 1.32% 5.56% 80.96%
LONG-TERM LIABILITIES
Long-Term Debt $39.50M $39.40M $39.30M
YoY Change 0.25% 63.49% 49.43%
Other Long-Term Liabilities $18.40M $18.70M $164.0K
YoY Change -1.6% 648.0% -87.66%
Total Long-Term Liabilities $57.90M $58.10M $164.0K
YoY Change -0.34% 118.42% -87.66%
TOTAL LIABILITIES
Total Short-Term Liabilities $46.20M $45.60M $50.78M
Total Long-Term Liabilities $57.90M $58.10M $164.0K
Total Liabilities $104.1M $103.6M $109.0M
YoY Change 0.48% 48.21% 77.51%
SHAREHOLDERS EQUITY
Retained Earnings -$815.2M
YoY Change 8.92%
Common Stock $880.8M
YoY Change 4.94%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $109.2M $60.81M $65.63M
YoY Change
Total Liabilities & Shareholders Equity $213.4M $164.4M $174.6M
YoY Change 29.81% 1.67% 15.0%

Cashflow Statement

Concept 2020 Q3 2019 Q3 2019 Q2
OPERATING ACTIVITIES
Net Income -$14.14M -$17.97M -$17.56M
YoY Change -21.31% 26.6% 32.22%
Depreciation, Depletion And Amortization $810.0K -$130.0K $1.180M
YoY Change -723.08% -140.62% 210.53%
Cash From Operating Activities -$4.680M -$22.22M -$12.88M
YoY Change -78.94% 354.4% 44.23%
INVESTING ACTIVITIES
Capital Expenditures -$240.0K -$1.940M -$3.200M
YoY Change -87.63% 312.77% 3100.0%
Acquisitions
YoY Change
Other Investing Activities -$5.140M $11.97M -$1.230M
YoY Change -142.94% 1085.15% -81.83%
Cash From Investing Activities -$5.380M $10.02M -$4.430M
YoY Change -153.69% 1790.57% -35.52%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.170M 13.06M 11.81M
YoY Change -68.07% 5.41% -21.94%
NET CHANGE
Cash From Operating Activities -4.680M -22.22M -12.88M
Cash From Investing Activities -5.380M 10.02M -4.430M
Cash From Financing Activities 4.170M 13.06M 11.81M
Net Change In Cash -5.890M 860.0K -5.500M
YoY Change -784.88% -89.29% 720.9%
FREE CASH FLOW
Cash From Operating Activities -$4.680M -$22.22M -$12.88M
Capital Expenditures -$240.0K -$1.940M -$3.200M
Free Cash Flow -$4.440M -$20.28M -$9.680M
YoY Change -78.11% 358.82% 9.63%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
cers Product Warranty Term
ProductWarrantyTerm
P1Y
CY2020Q3 us-gaap Secured Debt Current
SecuredDebtCurrent
4982000
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1857000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
84519000
CY2020Q3 cers Issuance Of Common Stock From Exercise Of Stock Options Or Warrants And Vesting Of Restricted Stock Units And Employee Stock Purchase Plans Purchases Value
IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesValue
4221000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4846000
CY2019Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
48000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-17967000
us-gaap Profit Loss
ProfitLoss
-45476000
us-gaap Profit Loss
ProfitLoss
-54321000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2298000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1781000
us-gaap Share Based Compensation
ShareBasedCompensation
13306000
us-gaap Share Based Compensation
ShareBasedCompensation
9612000
cers Non Cash Operating Lease Cost
NonCashOperatingLeaseCost
-962000
cers Non Cash Operating Lease Cost
NonCashOperatingLeaseCost
-1224000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-14139000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
109235000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20668000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-119000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2756000
cers Increase Decrease In Accrued Liabilities And Other Noncurrent Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherNoncurrentLiabilities
-1914000
CY2019Q1 cers Issuance Of Common Stock From Exercise Of Stock Options Or Warrants And Vesting Of Restricted Stock Units And Employee Stock Purchase Plans Purchases Value
IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesValue
684000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2878000
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
211000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-18792000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
69500000
cers Increase Decrease In Manufacturing And Development Payment Liability
IncreaseDecreaseInManufacturingAndDevelopmentPaymentLiability
-6288000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-9000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
63000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-32285000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-57277000
CY2019Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
9836000
CY2019Q2 cers Issuance Of Common Stock From Exercise Of Stock Options Or Warrants And Vesting Of Restricted Stock Units Value
IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsValue
558000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3139000
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
161000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-17562000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
65632000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1149000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8460000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
94028000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
34756000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
38017000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
62000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-57160000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
18784000
CY2019Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
7914000
CY2019Q3 cers Issuance Of Common Stock From Exercise Of Stock Options Or Warrants And Vesting Of Restricted Stock Units And Employee Stock Purchase Plans Purchases Value
IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesValue
1586000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3595000
CY2020Q2 cers Issuance Of Common Stock From Exercise Of Stock Options Or Warrants And Vesting Of Restricted Stock Units Value
IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsValue
1605000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
60808000
us-gaap Debt Securities Available For Sale Gain Loss
DebtSecuritiesAvailableForSaleGainLoss
-256000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-14000
cers Non Cash Interest Expense
NonCashInterestExpense
343000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-646000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
75000
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-218000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
6984000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
2854000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
76547000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
17803000
us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
-35000
us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
4993000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
39433000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
31080000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
83496000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
34003000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5949000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4490000
cers Work In Process Inventory Life Period
WorkInProcessInventoryLifePeriod
P1Y
CY2019Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
100000
CY2020Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
100000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37421000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
31587000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements requires management to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures of contingent assets and liabilities. On an ongoing basis, management evaluates its estimates, including those related to the nature and timing of satisfaction of performance obligations, the timing when the customer obtains control of products or services, the standalone selling price (“SSP”) of performance obligations, variable consideration, accounts receivable, inventory reserves, fair values of investments, the allowance for credit losses, stock-based compensation, intangible assets and goodwill, useful lives of intangible assets and property and equipment, income taxes, accrued liabilities, and incremental borrowing rate, among others. The Company bases its estimates on historical experience, future projections, and on various other assumptions that are believed to be reasonable under the circumstances. Actual results may differ from those estimates under different assumptions or conditions.</p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, available-for-sale securities and accounts receivable.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the Company’s investment policy, substantially all of the Company’s cash, cash equivalents and available-for-sale securities are maintained at major financial institutions of high credit standing. The Company monitors the financial credit worthiness of the issuers of its investments and limits the concentration in individual securities and types of investments that exist within its investment portfolio. Generally, all of the Company’s investments carry high credit quality ratings, which is in accordance with its investment policy. At September 30, 2020, the Company does not believe there is significant financial risk from non-performance by the issuers of the Company’s cash equivalents and short-term investments.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concentrations of credit risk with respect to trade receivables exist. On a regular basis, including at the time of sale, the Company performs credit evaluations of its significant customers that it expects to sell to on credit terms. Generally, the Company does not require collateral from its customers to secure accounts receivable. To the extent that the Company determines specific invoices or customer accounts may be uncollectible, the Company establishes an allowance for doubtful accounts against the accounts receivable on its condensed consolidated balance sheets and records a charge on its condensed consolidated statements of operations as a component of selling, general and administrative expenses.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had three customers and three customers that accounted for more than 10% of the Company’s outstanding trade receivables at both September 30, 2020 and December 31, 2019, respectively. These customers cumulatively represented approximately 59% and 56% of the Company’s outstanding trade receivables at September 30, 2020 and December 31, 2019, respectively. To date, the Company has not experienced collection difficulties from these customers.</p>
CY2020Q3 cers Cumulative Outstanding Trade Receivables Number Of Major Customers
CumulativeOutstandingTradeReceivablesNumberOfMajorCustomers
3
CY2019Q4 cers Cumulative Outstanding Trade Receivables Number Of Major Customers
CumulativeOutstandingTradeReceivablesNumberOfMajorCustomers
3
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
300000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2900000
us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P10Y
CY2020Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2000000.0
CY2019Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1900000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2020Q3 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2019Q3 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23637000
CY2019Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21492000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23305000
CY2020Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
us-gaap Guarantees Indemnifications And Warranties Policies
GuaranteesIndemnificationsAndWarrantiesPolicies
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Guarantee and Indemnification Arrangements</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes the fair value for guarantee and indemnification arrangements issued or modified by the Company. In addition, the Company monitors the conditions that are subject to the guarantees and indemnifications in order to identify if a loss has occurred. If the Company determines it is probable that a loss has occurred, then any such estimable loss would be recognized under those guarantees and indemnifications. Some of the agreements that the Company is a party to contain provisions that indemnify the counter party from damages and costs resulting from claims that the Company’s technology infringes the intellectual property rights of a third-party or claims that the sale or use of the Company’s products have caused personal injury or other damage or loss. The Company has not received any such requests for indemnification under these provisions and has not been required to make material payments pursuant to these provisions.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company generally provides for a <span style="-sec-ix-hidden:F_000461">one-year</span> warranty on certain of its INTERCEPT blood-safety products covering defects in materials and workmanship. The Company accrues costs associated with warranty obligations when claims become known and are estimable. The Company has not experienced significant or systemic warranty claims nor is it aware of any existing current warranty claims. Accordingly, the Company had not accrued for any future warranty costs for its products at September 30, 2020 and December 31, 2019.</p>
CY2020Q3 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
0
CY2019Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
0
CY2020Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
112627000
CY2020Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
909000
CY2020Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2000
CY2020Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
113534000
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
59478000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
114000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
59592000
CY2020Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
69843000
CY2020Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
70200000
CY2019Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
43822000
CY2019Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
43907000
CY2020Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
42784000
CY2020Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
43334000
CY2019Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
15656000
CY2019Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
15685000
CY2020Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
112627000
CY2020Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
113534000
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
59478000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
59592000
CY2019Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
0
CY2020Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2019Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2019Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2020Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2020Q3 us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
0
us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
300000
CY2019Q3 us-gaap Available For Sale Securities Gross Realized Gains
AvailableForSaleSecuritiesGrossRealizedGains
0
us-gaap Available For Sale Securities Gross Realized Gains
AvailableForSaleSecuritiesGrossRealizedGains
0
CY2019Q3 us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
0
us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
0
CY2020Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
113534000
CY2020Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
4279000
CY2019Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
5160000
CY2020Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
15181000
CY2019Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
14330000
CY2020Q3 us-gaap Inventory Net
InventoryNet
19460000
CY2019Q4 us-gaap Inventory Net
InventoryNet
19490000
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
10664000
CY2020Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3186000
CY2020Q3 cers Accrued Development Costs Current
AccruedDevelopmentCostsCurrent
1543000
CY2019Q4 cers Accrued Development Costs Current
AccruedDevelopmentCostsCurrent
1468000
CY2020Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4152000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3291000
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19545000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
20951000
us-gaap Operating Lease Payments
OperatingLeasePayments
2567000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
306000
CY2020Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y8M12D
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.089
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
828000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3500000
CY2020Q3 cers Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
16053000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
28892000
CY2020Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
9772000
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
19120000
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
846000
us-gaap Lessor Operating Lease Lease Not Yet Commenced Description
LessorOperatingLeaseLeaseNotYetCommencedDescription
the Company had no leases that have not yet commenced.
CY2020Q3 cers Payment For Manufacturing Of Entity Products
PaymentForManufacturingOfEntityProducts
8000000.0
CY2019Q3 cers Payment For Manufacturing Of Entity Products
PaymentForManufacturingOfEntityProducts
9800000
cers Payment For Manufacturing Of Entity Products
PaymentForManufacturingOfEntityProducts
22500000
CY2020Q3 cers Accrual For Manufacturing Of Entity Products
AccrualForManufacturingOfEntityProducts
9979000
CY2019Q4 cers Accrual For Manufacturing Of Entity Products
AccrualForManufacturingOfEntityProducts
8470000
CY2020Q3 us-gaap Accounts And Notes Receivable Net
AccountsAndNotesReceivableNet
1234000
CY2019Q4 us-gaap Accounts And Notes Receivable Net
AccountsAndNotesReceivableNet
1796000

Files In Submission

Name View Source Status
0001564590-20-048950-index-headers.html Edgar Link pending
0001564590-20-048950-index.html Edgar Link pending
0001564590-20-048950.txt Edgar Link pending
0001564590-20-048950-xbrl.zip Edgar Link pending
cers-10q_20200930.htm Edgar Link pending
cers-10q_20200930_htm.xml Edgar Link completed
cers-20200930.xsd Edgar Link pending
cers-20200930_cal.xml Edgar Link unprocessable
cers-20200930_def.xml Edgar Link unprocessable
cers-20200930_lab.xml Edgar Link unprocessable
cers-20200930_pre.xml Edgar Link unprocessable
cers-ex311_10.htm Edgar Link pending
cers-ex312_9.htm Edgar Link pending
cers-ex321_6.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending